Sai Life Sciences Q2FY26 Profit Doubles to ₹84 Crore, Revenue Jumps 36% YoY

Hyderabad, November 7, 2025: The share price of Sai Life Sciences Limited was trading 2.55% lower at ₹898 in early trade on Friday, despite the company posting strong Q2FY26 results. The stock opened at ₹922.30 and moved between an intraday high of ₹922.35 and a low of ₹886.45 so far.

Sai Life Sciences partners with leading biotech companies and global pharmaceutical innovators to accelerate research, development, and the commercialisation of new medicines. With a strong foundation built on safety, compliance, and scientific excellence, the company delivers comprehensive CRDMO (Contract Research, Development and Manufacturing Organisation) solutions spanning medicinal chemistry, process development, and manufacturing.

Q2FY26 Performance Highlights

Sai Life Sciences Limited reported a strong performance for the quarter and half year ended 30 September 2025, sustaining its growth momentum across key business segments. For Q2FY26, the company’s revenue from operations stood at ₹537 crore, reflecting a 36% year-on-year increase driven by solid growth in both CRO and CDMO services. EBITDA rose 43% to ₹156 crore, while profit after tax (PAT) doubled to ₹84 crore compared to ₹42 crore in Q2FY25. EBITDA margin improved to 29% from 28% in the same period last year, and PAT margin expanded to 16% from 11%.

September also marked the close of the first half of FY26. For the six months ended 30 September 2025, Sai Life Sciences reported revenue from operations of ₹1,034 crore, up 53% from ₹675 crore in H1FY25. EBITDA for the period stood at ₹281 crore, registering a 101% growth from ₹140 crore, while PAT surged 414% to ₹144 crore compared with ₹28 crore in the previous year. The strong half-yearly performance was driven by healthy demand across the company’s discovery, development, and manufacturing services, supported by improved operating leverage and prudent cost management.

What Does the Management Say?

Managing Director and CEO, Krishna Kanumuri, said that this growth in numbers was driven by consistent execution, healthy client relationships, and recurring traction in the late-stage and commercial programs. He also stated that investment in the latest and advances technologies is the key factor for the company’s position in long-term competitiveness and readiness.

The Whole time Director and CFO, Siva Chittor, underlined the ₹248 crore capex that was recorded in H1FY26, which was used in growing the R&D capacity and introducing new technology provisions. He also made an affirmation that the company will adopt a disciplined financial model, improvement in margin, and efficient handling of capital deployment to sustain long-term growth and profitability.

Share Price Update

As of 9:34 AM, the share price of Sai Life Sciences was trading at ₹898, a 2.55% from its previous close. The company has a market capitalization of 18.61K crore, and recorded a 52-week high of ₹943 and a 52-week low of ₹636.

REF: https://nsearchives.nseindia.com/corporate/SAILIFE_06112025220621_LODR_-_Reg_30_Press_Release.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations